All In Biotech

Drug Trial Radar · NCT07774364

Safety and Efficacy of Topical AT-004 1% in Participants With Acne Vulgaris (AV)

A Phase 2 Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Topical AT-004 1% in Participants With Acne Vulgaris.

Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

63

Actual

Start

Feb 2, 2026

Primary completion

Jul 15, 2026

Study completion Jul 29, 2026

Sponsor

Lead sponsor
Arctic TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Blueskin AS
First posted
Aug 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Double blinded, randomized, placebo-controlled trial to determine the safety and efficacy of topical AT-004 therapy in participants with acne vulgaris, including assessment of reduction in the number of acne lesions and IGA. A PK sub-study will be performed in a subset of participants. Participants with moderate to severe acne vulgaris, aged 18 to 45 years, who are likely to meet inclusion and none of the exclusion criteria will be invited for a screening visit. The study include a screening period, treatment phase with the baseline visit at day 1 and a follow -up visits at week 4, 8 and week 12. All participants will be followed by a follow-up call within 4 weeks from last visit. A total number of 60 participants will be enrolled.

Conditions

  • Acne Vulgaris on the Face

Interventions

  • AT-004Drug

    Participants receiving AT-004 topical application

  • PlaceboDrug

    Participants receiving matching placebo topical application

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: 12 weeks
  2. Laboratory safety parametersTime frame: 12 weeks
  3. Incidence of inflammatory and non-inflammatory lesionsTime frame: 12 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Sanos Gandrup Clinic

    Gandrup, Denmark

  • Herlev Sanos Clinic

    Herlev, Denmark

  • Sanos Vejle Clinic

    Vejle, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.